المؤلفون: Yu-Ping Chang, Yi-Hsuan Tsai, Yu-Mu Chen, Kuo-Tung Huang, Chiu-Ping Lee, Po-Yuan Hsu, Hung-Chen Chen, Meng-Chih Lin, Yung-Che Chen

المصدر: Respiratory Research, Vol 25, Iss 1, Pp 1-14 (2024)

مصطلحات موضوعية: Asthma-COPD overlap, Interleukin 6 receptor, miR-125b-5p, TP53-regulated inhibitor of apoptosis 1, Diseases of the respiratory system, RC705-779

الوصف: Abstract Background Among patients with chronic obstructive pulmonary disease (COPD), some have features of both asthma and COPD—a condition categorized as asthma-COPD overlap (ACO). Our aim was to determine whether asthma- or COPD-related microRNAs (miRNAs) play a role in the pathogenesis of ACO. Methods A total of 22 healthy subjects and 27 patients with ACO were enrolled. We selected 6 miRNAs that were found to correlate with COPD and asthma. The expression of miRNAs and target genes was analyzed using quantitative reverse-transcriptase polymerase chain reaction. Cell apoptosis and intracellular reactive oxygen species production were evaluated using flow cytometry. In vitro human monocytic THP-1 cells and primary normal human bronchial epithelial (NHBE) cells under stimuli with cigarette smoke extract (CSE) or ovalbumin (OVA) allergen or both were used to verify the clinical findings. Results We identified the upregulation of miR-125b-5p in patients with ACO and in THP-1 cells stimulated with CSE plus OVA allergen. We selected 16 genes related to the miR-125b-5p pathway and found that IL6R and TRIAP1 were both downregulated in patients with ACO and in THP-1 cells stimulated with CSE plus OVA. The percentage of late apoptotic cells increased in the THP-1 cell culture model when stimulated with CSE plus OVA, and the effect was reversed by transfection with miR-125b-5p small interfering RNA (siRNA). The percentage of reactive oxygen species-producing cells increased in the NHBE cell culture model when stimulated with CSE plus OVA, and the effect was reversed by transfection with miR-125b-5p siRNA. In NHBE cells, siRNA transfection reversed the upregulation of STAT3 under CSE+OVA stimulation. Conclusions Our study revealed that upregulation of miR-125b-5p in patients with ACO mediated late apoptosis in THP-1 cells and oxidative stress in NHBE cells via targeting IL6R and TRIAP1. STAT3 expression was also regulated by miR-125b-5p.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1465-993XTest

الوصول الحر: https://doaj.org/article/ac489a5f0b784f2c951a5f8324e94e76Test

المؤلفون: Livia Lenzini, Elisabetta Iori, Monica Vettore, Giorgia Gugelmo, Claudia Radu, Andrea Padoan, Gianni Carraro, Paolo Simioni, Lorenzo Calò, Angelo Avogaro, Gian Paolo Rossi, Nicola Vitturi

المصدر: Journal of Clinical Medicine, Vol 13, Iss 1, p 218 (2023)

مصطلحات موضوعية: Fabry disease, interleukin 6 receptor, exosomes, inflammation, Medicine

الوصف: Fabry disease (FD) is an X-linked lysosome storage disease that results in the accumulation of globotriaosylceramide (Gb3) throughout the body leading to irreversible target organ damage. As the role of secondary mediators (inflammatory molecules) and their mechanisms has not been fully elucidated, we focused on the interleukin (IL)-6 system in adult FD patients and in matched healthy subjects. To obtain insights into the complex regulation of IL-6 actions, we used a novel approach that integrates information from plasma and exosomes of FD patients (n = 20) and of healthy controls (n = 15). Soluble IL-6 receptor (sIL-6R) levels were measured in plasma with the ELISA method, and membrane-bound IL-6R was quantified in plasma and urinary exosomes using flow cytometry. In FD patients, the levels of soluble IL-6R in plasma were higher than in control subjects (28.0 ± 5.4 ng/mL vs. 18.9 ± 5.4 ng/mL, p < 0.0001); they were also higher in FD subjects with the classical form as compared to those with the late-onset form of the disease (36.0 ± 11.4 ng/mL vs. 26.1 ± 4.5 ng/mL, p < 0.0001). The percentage of urinary exosomes positive for IL-6R was slightly lower in FD (97 ± 1 vs. 100 ± 0% of events positive for IL-6R, p < 0.05); plasma IL-6 levels were not increased. These results suggest a potential role of IL-6 in triggering the inflammatory response in FD. As in FD patients only the levels of sIL-6Rs are consistently higher than in healthy controls, the IL-6 pathogenic signal seems to prevail over the homeostatic one, suggesting a potential mechanism causing multi-systemic damage in FD.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2077-0383/13/1/218Test; https://doaj.org/toc/2077-0383Test

الوصول الحر: https://doaj.org/article/4e784599214e4d22bb1509edba329f96Test

المؤلفون: Sundaresan Bhavaniramya, Ashokkumar Sibiya, Abdulaziz S. Alothaim, Ayoub Al Othaim, Vanajothi Ramar, Alaguraj Veluchamy, Palanisamy Manikandan, Baskaralingam Vaseeharan

المصدر: Journal of King Saud University: Science, Vol 34, Iss 4, Pp 101924- (2022)

مصطلحات موضوعية: Interleukin 6, Interleukin 6 receptor, Goat, Goat Milk, Peptide docking, MD simulation, Science (General), Q1-390

الوصف: The function of Immune control, haematopoiesis, and inflammation all depend on the cytokine Interleukin 6 (IL-6), and higher expression of IL-6 is seen in COVID-19 and other diseases. The immune protein IL-6 activation is dependent on binding interactions with IL-6Rα, mIL-6R, and sIL-6R for its cellular function. Termination of these reaction could benefit for controlling the over-expression in COVID-19 patients and that may arise as inhibitors for controlling COVID-19. Traditionally, the goat milk has been prescribed as medicine in ayurvedic practice and through this work, we have explored the benefits of peptides from goat milk as IL-6 inhibitors, and it have the potential of inhibiting the over expression of IL-6 and control the COVID-19 disease. Computational experiments have shown that goat peptides had strong interactions with IL-6, with higher scoring profiles and energy efficiency ranging from −6.00 kcal/mol to −9.00 kcal/mol in docking score and −39.00 kcal/mol in binding energy. Especially the YLGYLEQLLR, VLVLDTDYK and AMKPWIQPK peptides from goat milk holds better scoring and shows strong interactions were identified as the most potential IL-6 inhibitor candidates in this study. Peptides from Goat proteins, which are capable of binding to the IL-6 receptor with strong binding conformations, have no negative effects on other immune system proteins.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S1018364722001057Test; https://doaj.org/toc/1018-3647Test

الوصول الحر: https://doaj.org/article/731cd401da1f462790987ccd0b9c0642Test

المؤلفون: Min Zhang, Ye Bai, Yutong Wang, Huijie Cui, Mingshuang Tang, Lanbing Wang, Xin Wang, Dongqing Gu

المصدر: Frontiers in Immunology, Vol 13 (2022)

مصطلحات موضوعية: interleukin 6 receptor, variant, cardiovascular diseases, inflammatory diseases, phenotypes, Immunologic diseases. Allergy, RC581-607

الوصف: BackgroundGenetic studies have linked polymorphisms in the interleukin 6 receptor (IL6R) gene to the risk of multiple human diseases and phenotypes, yet have reported inconsistent results. We aimed to synthesize current knowledge of variants in the IL6R gene on the risk of diseases and phenotypes.MethodsWe searched the Medline and Embase databases to identify relevant publications. Meta-analysis was performed utilizing DerSimonian and Laird random-effects model. We also graded cumulative evidence for significant associations. Furthermore, phenome-wide analyses and functional annotations were performed for variants with strong evidence.ResultsWe included 155 studies for evaluating the associations between 80 polymorphisms in the IL6R gene and the risk of 102 human diseases and 98 phenotypes. We conducted 58 main meta-analyses, and 41 significant associations were identified. Strong evidence was assigned to 29 associations that investigated ten variants (rs2228145, rs4129267, rs7529229, rs4537545, rs7518199, rs4845625, rs4553185, rs4845618, rs4845371, and rs6667434) related to the risk of four cardiovascular diseases (coronary heart disease, coronary artery disease, atherosclerosis, and abdominal aortic aneurysms), four inflammatory diseases (rheumatoid arthritis, Crohn’s disease, dermatitis, and asthma), and concentration of four phenotypes (C-reactive protein, fibrinogen, IL-6, and sIL-6R). Furthermore, phenome-wide analysis verified that rs2228145 associated with asthma and dermatitis risk. Functional analyses indicated that these polymorphisms fall within exon, enhancer regions.ConclusionsOur study comprehensively summarizes current data on the genetic architecture of the IL6R gene and highlights the pharmacological targeting potential of IL-6R on cardiovascular and inflammatory diseases.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fimmu.2022.860703/fullTest; https://doaj.org/toc/1664-3224Test

الوصول الحر: https://doaj.org/article/26954f54d729403fb4fda54c5a61b600Test

المؤلفون: Lenzini, Livia, Iori, Elisabetta, Vettore, Monica, Gugelmo, Giorgia, Radu, Claudia, Padoan, Andrea, Carraro, Gianni, Simioni, Paolo, Calò, Lorenzo, Avogaro, Angelo, Rossi, Gian Paolo, Vitturi, Nicola

المساهمون: Lenzini, Livia, Iori, Elisabetta, Vettore, Monica, Gugelmo, Giorgia, Radu, Claudia, Padoan, Andrea, Carraro, Gianni, Simioni, Paolo, Calò, Lorenzo, Avogaro, Angelo, Rossi, Gian Paolo, Vitturi, Nicola

مصطلحات موضوعية: exosome, Fabry disease, inflammation, interleukin 6 receptor

الوصف: Fabry disease (FD) is an X-linked lysosome storage disease that results in the accumulation of globotriaosylceramide (Gb3) throughout the body leading to irreversible target organ damage. As the role of secondary mediators (inflammatory molecules) and their mechanisms has not been fully elucidated, we focused on the interleukin (IL)-6 system in adult FD patients and in matched healthy subjects. To obtain insights into the complex regulation of IL-6 actions, we used a novel approach that integrates information from plasma and exosomes of FD patients (n = 20) and of healthy controls (n = 15). Soluble IL-6 receptor (sIL-6R) levels were measured in plasma with the ELISA method, and membrane-bound IL-6R was quantified in plasma and urinary exosomes using flow cytometry. In FD patients, the levels of soluble IL-6R in plasma were higher than in control subjects (28.0 ± 5.4 ng/mL vs. 18.9 ± 5.4 ng/mL, p < 0.0001); they were also higher in FD subjects with the classical form as compared to those with the late-onset form of the disease (36.0 ± 11.4 ng/mL vs. 26.1 ± 4.5 ng/mL, p < 0.0001). The percentage of urinary exosomes positive for IL-6R was slightly lower in FD (97 ± 1 vs. 100 ± 0% of events positive for IL-6R, p < 0.05); plasma IL-6 levels were not increased. These results suggest a potential role of IL-6 in triggering the inflammatory response in FD. As in FD patients only the levels of sIL-6Rs are consistently higher than in healthy controls, the IL-6 pathogenic signal seems to prevail over the homeostatic one, suggesting a potential mechanism causing multi-systemic damage in FD.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38202225; info:eu-repo/semantics/altIdentifier/wos/WOS:001141332200001; volume:13; issue:1; firstpage:1; lastpage:8; numberofpages:8; journal:JOURNAL OF CLINICAL MEDICINE; https://hdl.handle.net/11577/3504610Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85181920922

الإتاحة: https://doi.org/10.3390/jcm13010218Test
https://hdl.handle.net/11577/3504610Test

المؤلفون: Mohammad Hendra Setia Lesmana, Nguyen Quoc Khanh Le, Wei-Che Chiu, Kuo-Hsuan Chung, Chih-Yang Wang, Lalu Muhammad Irham, Min-Huey Chung

المصدر: Biomedicines; Volume 10; Issue 8; Pages: 1947

مصطلحات موضوعية: depression, genomic analysis, drug repurposing, functional annotation, bioinformatics, genetic, genomic variants, interleukin 6 receptor, sarilumab, satralizumab

الوصف: From inadequate prior antidepressants that targeted monoamine neurotransmitter systems emerged the discovery of alternative drugs for depression. For instance, drugs targeted interleukin 6 receptor (IL6R) in inflammatory system. Genomic analysis-based drug repurposing using single nucleotide polymorphism (SNP) inclined a promising method for several diseases. However, none of the diseases was depression. Thus, we aimed to identify drug repurposing candidates for depression treatment by adopting a genomic-analysis-based approach. The 5885 SNPs obtained from the machine learning approach were annotated using HaploReg v4.1. Five sets of functional annotations were applied to determine the depression risk genes. The STRING database was used to expand the target genes and identify drug candidates from the DrugBank database. We validated the findings using the ClinicalTrial.gov and PubMed databases. Seven genes were observed to be strongly associated with depression (functional annotation score = 4). Interestingly, IL6R was auspicious as a target gene according to the validation outcome. We identified 20 drugs that were undergoing preclinical studies or clinical trials for depression. In addition, we identified sarilumab and satralizumab as drugs that exhibit strong potential for use in the treatment of depression. Our findings indicate that a genomic-analysis-based approach can facilitate the discovery of drugs that can be repurposed for treating depression.

وصف الملف: application/pdf

العلاقة: Drug Discovery; https://dx.doi.org/10.3390/biomedicines10081947Test

الإتاحة: https://doi.org/10.3390/biomedicines10081947Test

المؤلفون: Bhavaniramya, Sundaresan, Sibiya, Ashokkumar, Alothaim, Abdulaziz S., Al Othaim, Ayoub, Ramar, Vanajothi, Veluchamy, Alaguraj, Manikandan, Palanisamy, Vaseeharan, Baskaralingam

المساهمون: Biological and Environmental Science and Engineering (BESE) Division, Center for Desert Agriculture, Biomaterials and Biotechnology in Animal Health Lab, Department of Animal Health and Management, Alagappa University, Karaikudi, Tamil Nadu, India, Department of Biology, College of Science in Zulfi, Majmaah University, Majmaah 11952, Saudi Arabia, Department of Medical Laboratories, College of Applied Medical Sciences, Majmaah University, Al-Majmaah, 11952, Saudi Arabia, Department of Biomedical Science, Bharathidasan University, Tiruchirappalli-620024. India, Greenlink Analytical and Research Laboratory India Private Limited, Coimbatore 641 014, India

مصطلحات موضوعية: Goat, Interleukin 6 receptor, MD simulation, Interleukin 6, Goat Milk, Peptide Docking, Covid-19

الوصف: The function of Immune control, haematopoiesis, and inflammation all depend on the cytokine Interleukin 6 (IL-6), and higher expression of IL-6 is seen in COVID-19 and other diseases. The immune protein IL-6 activation is dependent on binding interactions with IL-6Rα, mIL-6R, and sIL-6R for its cellular function. Termination of these reaction could benefit for controlling the over-expression in COVID-19 patients and that may arise as inhibitors for controlling COVID-19. Traditionally, the goat milk has been prescribed as medicine in ayurvedic practice and through this work, we have explored the benefits of peptides from goat milk as IL-6 inhibitors, and it have the potential of inhibiting the over expression of IL-6 and control the COVID-19 disease. Computational experiments have shown that goat peptides had strong interactions with IL-6, with higher scoring profiles and energy efficiency ranging from -6.00 kcal/mol to -9.00 kcal/mol in docking score and -39.00 kcal/mol in binding energy. Especially the YLGYLEQLLR, VLVLDTDYK and AMKPWIQPK peptides from goat milk holds better scoring and shows strong interactions were identified as the most potential IL-6 inhibitor candidates in this study. Peptides from Goat proteins, which are capable of binding to the IL-6 receptor with strong binding conformations, have no negative effects on other immune system proteins. ; SB thankfully acknowledges UGC Kothari post-doctoral fellowship award (F.4-2/2006(BSRYBL/20-21/0014) and Alagappa University for providing the necessary facilities to carry out this work. The author would like to thank Deanship of Scientific Research at Majmaah University for supporting this work.

وصف الملف: application/pdf

العلاقة: https://www.sciencedirect.com/science/article/pii/S1018364722001057Test; Bhavaniramya, S., Sibiya, A., Alothaim, A. S., Al Othaim, A., Ramar, V., Veluchamy, A., Manikandan, P., & Vaseeharan, B. (2022). Evaluating the structural and immune mechanism of Interleukin-6 for the investigation of Goat Milk peptides as potential treatments for COVID-19. Journal of King Saud University - Science, 101924. https://doi.org/10.1016/j.jksus.2022.101924Test; Journal of King Saud University. Science; PMC8875951; http://hdl.handle.net/10754/675642Test

الإتاحة: https://doi.org/10.1016/j.jksus.2022.101924Test
http://hdl.handle.net/10754/675642Test

المؤلفون: Soamarat Vilaiyuk, Butsabong Lerkvaleekul, Sirisucha Soponkanaporn, Chavachol Setthaudom, Supranee Buranapraditkun

المصدر: Central European Journal of Immunology, Vol 44, Iss 2, Pp 150-158 (2019)

مصطلحات موضوعية: interleukin 6, interleukin 6 receptor, systemic juvenile idiopathic arthritis, juvenile idiopathic arthritis, tocilizumab, anti-interleukin 6 receptor antibody, correlation, Medicine

وصف الملف: electronic resource

العلاقة: https://www.termedia.pl/Correlations-between-serumTest-interleukin-6-serum-soluble-interleukin-6-receptor-and-disease-activity-in-systemic-juvenile-idiopathic-arthritis-patients-treated-with-or-without-tocilizumab,10,37374,1,1.html; https://doaj.org/toc/1426-3912Test; https://doaj.org/toc/1644-4124Test

الوصول الحر: https://doaj.org/article/08d39d2b63414e54822c14ab61cf5b40Test

المؤلفون: Le Joncour, Alexandre, Biard, Lucie, Vautier, Mathieu, Bugaut, Hélène, Mékinian, Arsène, Maalouf, Georgina, Vieira, Matheus, Marcelin, Anne-Geneviève, Rosenzwajg, Michelle, Klatzmann, David, Corvol, Jean-Christophe, Paccoud, Olivier, Carillion, Aude, Salem, Joe-Elie, Cacoub, Patrice, Boulaftali, Yacine, Saadoun, David

المساهمون: CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Epidemiology and Clinical Statistics for Tumor, Respiratory, and Resuscitation, Centre for Research in Epidemiology and Statistics, Conservatoire National des Arts et Métiers CNAM (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers CNAM (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de médecine interne CHU Caen, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Saint-Antoine AP-HP, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre d'investigation clinique Biothérapie CHU Pitié-Salpêtrière (CIC-BTi), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Immunologie - Immunopathologie - Immunothérapie CHU Pitié Salpêtrière (I3), CHU Charles Foix AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition CHU Pitié Salpêtrière (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière AP-HP, Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord

المصدر: ISSN: 0340-6245 ; Thrombosis and Haemostasis ; https://hal.sorbonne-universite.fr/hal-03099470Test ; Thrombosis and Haemostasis, 2020, 120 (12), pp.1733-1735. ⟨10.1055/s-0040-1718732⟩.

مصطلحات موضوعية: COVID-19 SARS-CoV-2 Platelets Neutrophils Monocytes Leukocytes-Platelets aggregates thrombosis interleukin 6 receptor WORD COUNT :1197 References 25, Table 1, Figure 1, COVID-19, SARS-CoV-2, Platelets, Neutrophils, Monocytes, Leukocytes-Platelets aggregates, thrombosis, interleukin 6 receptor WORD COUNT :1197, References 25, [SDV.IMM]Life Sciences [q-bio]/Immunology

الوصف: International audience ; Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the world. Besides severe pneumonia with acute respiratory distress syndrome (ARDS), it has been more recently highlighted that SARS-CoV-2 could predispose to thrombotic disease, both in venous and arterial circulations.[1] Lung autopsy from severe COVID-19 patients revealed high recruitment of innate immune cells including neutrophils and macrophages contributing to the cytokine storm as well as microthrombi.[2] Given the central role of platelets in inflammation and thrombosis, and more specifically leucocyte–platelet aggregates that have been implicated in arterial and venous thrombosis, we aimed to explore neutrophil–platelet aggregate (NPA) and monocyte–platelet aggregate (MPA) in patients hospitalized in a medical ward for COVID-19 infection.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33124027; hal-03099470; https://hal.sorbonne-universite.fr/hal-03099470Test; https://hal.sorbonne-universite.fr/hal-03099470/documentTest; https://hal.sorbonne-universite.fr/hal-03099470/file/MANUSCRIPT_LPA_COVID_Letter_R_LM.pdf_1708_TrackChanges.pdfTest; PUBMED: 33124027; PUBMEDCENTRAL: PMC7869059; WOS: 000583041800002

الإتاحة: https://doi.org/10.1055/s-0040-1718732Test
https://hal.sorbonne-universite.fr/hal-03099470Test
https://hal.sorbonne-universite.fr/hal-03099470/documentTest
https://hal.sorbonne-universite.fr/hal-03099470/file/MANUSCRIPT_LPA_COVID_Letter_R_LM.pdf_1708_TrackChanges.pdfTest

المؤلفون: Remigiusz Kazimierczyk, Piotr Blaszczak, Małgorzata Jasiewicz, Małgorzata Knapp, Katarzyna Ptaszynska-Kopczynska, Bozena Sobkowicz, Ewa Waszkiewicz, Ryszard Grzywna, Wlodzimierz J. Musial, Karol A. Kaminski

المصدر: Platelets, Vol 30, Iss 4, Pp 445-451 (2019)

مصطلحات موضوعية: interleukin 6, interleukin 6 receptor, platelets, pulmonary arterial hypertension, sdf-1, Diseases of the blood and blood-forming organs, RC633-647.5

الوصف: Inflammatory processes and platelet activity play an important role in the pathophysiology of pulmonary arterial hypertension (PAH). Enhanced IL-6 signaling and higher concentration of stromal-derived factor alpha (SDF-1) have been previously shown to be linked with prognosis in PAH. We hypothesized that platelets of PAH patients have higher content of IL-6 and SDF-1 and thus are involved in disease progression. We enrolled into study 22 PAH patients and 18 healthy controls. Patients with PAH presented significantly higher plasma concentrations and platelet contents of IL-6, sIL-6R, and SDF-1 than healthy subjects (platelet content normalized to protein concentration: IL-6 (0.85*10–10 [0.29 – 1.37] vs. 0.45*10–10 [0.19–0.65], sIL-6R 1.54*10–7 [1.32–2.21] vs. 1.14*10–7 [1.01–1.28] and SDF-1 (2.72*10–7 [1.85–3.23] vs. 1.70*10–7 [1.43–2.60], all p

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/0953-7104Test; https://doaj.org/toc/1369-1635Test

الوصول الحر: https://doaj.org/article/d651738f0d6449ffa12b63a156920268Test